BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 21276372)

  • 21. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET/CT and MRI for Identifying Axillary Lymph Node Metastases in Breast Cancer Patients: Systematic Review and Meta-Analysis.
    Zhang X; Liu Y; Luo H; Zhang J
    J Magn Reson Imaging; 2020 Dec; 52(6):1840-1851. PubMed ID: 32567090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Pennant M; Takwoingi Y; Pennant L; Davenport C; Fry-Smith A; Eisinga A; Andronis L; Arvanitis T; Deeks J; Hyde C
    Health Technol Assess; 2010 Oct; 14(50):1-103. PubMed ID: 21044553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
    J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET-CT and MR Imaging in the Management of Axillary Nodes in Early Stage Breast Cancer.
    Baran MT; Gundogdu H; Demiral G; Kupik O; Arpa M; Pergel A
    J Coll Physicians Surg Pak; 2020 Sep; 30(9):946-950. PubMed ID: 33036679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
    Sutcliffe P; Connock M; Shyangdan D; Court R; Kandala NB; Clarke A
    Health Technol Assess; 2013 Sep; 17(42):1-274. PubMed ID: 24070110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
    Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A
    Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging tests for the detection of osteomyelitis: a systematic review.
    Llewellyn A; Jones-Diette J; Kraft J; Holton C; Harden M; Simmonds M
    Health Technol Assess; 2019 Oct; 23(61):1-128. PubMed ID: 31670644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer.
    Huang SM; Yin L; Yue JL; Li YF; Yang Y; Lin ZC
    Medicine (Baltimore); 2018 Dec; 97(50):e13344. PubMed ID: 30557983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
    Fehr MK; Hornung R; Varga Z; Burger D; Hess T; Haller U; Fink D; von Schulthess GK; Steinert HC
    Breast J; 2004; 10(2):89-93. PubMed ID: 15009033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
    Heiranizadeh N; Rafiei Shahamabadi M; Dehghan HR; Jafari-Nedooshan J; Kargar S; Zare M; Amooei A; Shiryazdi SM; Broomand MA; Moravej MT; Sadri Z
    Asian Pac J Cancer Prev; 2022 Aug; 23(8):2561-2571. PubMed ID: 36037108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
    Shao M; Zi J; Wen G
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging.
    Memarsadeghi M; Riedl CC; Kaneider A; Galid A; Rudas M; Matzek W; Helbich TH
    Radiology; 2006 Nov; 241(2):367-77. PubMed ID: 17057065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.